文献速递妇科

子宫肌瘤患者子宫肌瘤剔除术与子宫切除术的成本效益比较

Cost-effectiveness of Myomectomy versus Hysterectomy in Women with Uterine Fibroids.
PubMed 文献 · J Minim Invasive Gynecol · 2023-06-05

本研究采用马尔可夫模型,模拟10000名40岁不再要求妊娠的子宫肌瘤女性,比较子宫肌瘤剔除术、保留卵巢的子宫切除术及不保留卵巢的子宫切除术的成本效益。结果显示子宫肌瘤剔除术最具成本效益,成本为528217美元并提供19.38质量调整生命年;在愿意支付阈值为每QALY 100000美元时,两种子宫切除术均不具成本效益。

要点

  • 子宫肌瘤剔除术成本为528217美元,提供19.38 QALYs,为最佳价值策略。
  • 保留卵巢的子宫切除术每额外获得1个QALY平均成本为613144美元,不具成本效益。
  • 若子宫肌瘤剔除术后每年需治疗的新发症状性肌瘤风险超过13%(基线3.6%),或术后生活质量低于0.815(基线0.834),则剔除术不再具成本效益。

核心结论

  • 对于40岁子宫肌瘤女性,子宫肌瘤剔除术是优于子宫切除术的最佳治疗选择。
  • 子宫切除术后冠状动脉疾病风险增加及其相关成本、对发病率和生活质量的影响,使子宫切除术成为成本更高且效果更差的长期策略。

研究设计与样本

  • 研究采用马尔可夫模型,纳入不再要求妊娠的子宫肌瘤女性。
  • 研究视角为卫生系统视角,模拟10000名40岁女性的假设队列。
  • 比较的干预措施为子宫肌瘤剔除术、保留卵巢的子宫切除术和不保留卵巢的子宫切除术。
  • 结局指标为质量调整生命年(QALYs)和总治疗成本,并开展敏感性分析以检验不确定模型输入的影响。

主要发现

  • 子宫肌瘤剔除术成本为528217美元,提供19.38 QALYs,为最佳价值策略。
  • 在愿意支付阈值为每QALY增益100000美元时,保留卵巢的子宫切除术和不保留卵巢的子宫切除术均不具成本效益。
  • 保留卵巢的子宫切除术比子宫肌瘤剔除术提供更多获益,但每额外获得1个QALY的平均成本为613144美元。
  • 敏感性分析显示,若子宫肌瘤剔除术后每年需治疗的新发症状性子宫肌瘤风险超过13%(基线为3.6%),则在愿意支付金额为100000美元时,子宫肌瘤剔除术不再具成本效益。
  • 敏感性分析显示,若子宫肌瘤剔除术后生活质量低于0.815(基线为0.834),则在愿意支付金额为100000美元时,子宫肌瘤剔除术不再具成本效益。

关键数值与推荐

  • 子宫肌瘤剔除术成本为528217美元,提供19.38 QALYs。
  • 保留卵巢的子宫切除术每额外获得1个QALY的平均成本为613144美元。
  • 愿意支付阈值为每QALY增益100000美元。
  • 子宫肌瘤剔除术后每年需治疗的新发症状性子宫肌瘤风险的阈值为13%(基线为3.6%)。
  • 子宫肌瘤剔除术后生活质量的阈值为0.815(基线为0.834)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Increasing evidence suggests that hysterectomy to treat uterine fibroids (UFs), even with ovarian conservation (OC), is associated with a 33% increased risk of coronary artery disease (CAD). We sought to compare the cost-effectiveness of various treatment approaches for UFs to understand the trade-offs among development of CAD vs new fibroids. DESIGN: We developed a Markov model to include women with UFs who no longer desired pregnancy. The outcomes of interest were quality-adjusted life-years (QALYs) and total treatment costs. We conducted sensitivity analyses to test the effect of uncertain model inputs. SETTING: Health system perspective. PATIENTS: A hypothetical cohort of 10 000 40-year-old women. INTERVENTIONS: Myomectomy, hysterectomy with OC, and hysterectomy without OC. MEASUREMENTS AND MAIN RESULTS: Myomectomy was the best-value strategy, costing US$528 217 and providing 19.38 QALYs. Neither hysterectomy with OC nor hysterectomy without OC was found to be cost-effective, assuming a willingness-to-pay threshold of $100 000 per QALY gain as hysterectomy with OC provided more benefit than myomectomy at an average cost of $613 144 to gain one additional QALY. The sensitivity analyses showed that if the risk of new symptomatic UFs that required treatment after myomectomy was more than 13%, annually (base case, 3.6%), or the quality of life after myomectomy was less than 0.815 (base case, 0.834), then myomectomy would no longer be cost-effective, under a willingness-to-pay amount of US$100 000. CONCLUSION: Myomectomy is an optimal treatment of UFs compared with hysterectomy among women aged 40 years. The increased risk of CAD after hysterectomy and its associated costs and the effects on morbidity and quality of life made hysterectomy a costlier and less effective long-term strategy.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Thao V, Moriarty JP, Stewart EA, et al. Cost-effectiveness of Myomectomy versus Hysterectomy in Women with Uterine Fibroids. J Minim Invasive Gynecol. 2023. PMID: 37286130. doi:10.1016/j.jmig.2023.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。